What is Arcellx Inc (ACLX) stock price today?

Arcellx Inc (ACLX) currently trades at $115.07 per share. The stock has a market capitalization of $6.73B and a P/E ratio of —x.

Is ACLX stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Arcellx Inc has a Smart Value Score of 22/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 1/9 and Altman Z-Score is -0.03.

What is Arcellx Inc's revenue and earnings?

Arcellx Inc has trailing twelve-month (TTM) revenue of $22.29M with profit margins of 0.00%. Earnings per share (EPS) is $-4.07.

Is Arcellx Inc financially healthy?

Arcellx Inc's Piotroski F-Score is 1/9 (weak financial health). The Altman Z-Score of -0.03 places it in the distress.

ACLX

Arcellx Inc

NASDAQ: ACLX · HEALTHCARE · BIOTECHNOLOGY

$115.07

+0.00% today

Updated 2026-04-28

Market cap

$6.73B

P/E ratio

—

P/S ratio

302.04x

EPS (TTM)

$-4.07

Dividend yield

—

52W range

$48 – $115

Volume

2.8M

Market cap

$6.73B

P/E ratio

—

P/S ratio

302.04x

EPS (TTM)

$-4.07

Dividend yield

—

52W range

$48 – $115

Volume

2.8M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.0

Growth

4.8

Quality

2.5

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-0.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$112.20

-2.49%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy0 Buy18 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -0.03 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-58.94M

- Revenue declining -89.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$17.91M	$110.32M	$107.94M	$22.29M	$22.29M
Net income	$-188.68M	$-70.69M	$-107.35M	$-228.93M	$-58.11M
EPS	—	—	—	—	$-4.07
Free cash flow	$-101.58M	$186.15M	$-96.90M	$-212.59M	$-58.94M
Profit margin	-1,053.37%	-64.08%	-99.46%	-1,027.25%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ACLX	$6.73B	22	4.0	2.5	5.0	4.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Arcellx Inc trades at $115.07. Our Smart Value Score of 22/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -0.03, it sits in the distress. TTM revenue stands at $22.29M.

Frequently asked questions

What is Arcellx Inc's stock price?

Arcellx Inc (ACLX) trades at $115.07.

Is Arcellx Inc overvalued?

Smart Value Score 22/100 (Grade F, Strong Sell).

What is the price target of Arcellx Inc (ACLX)?

The analyst target price is $112.20, representing -2.5% downside from the current price of $115.07.

What is Arcellx Inc's revenue?

TTM revenue is $22.29M.

Piotroski F-Score?

1/9 — weak financial health.

Altman Z-Score?

-0.03 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio302.04x

ROE-53.40%

Beta0.25

50D MA$110.81

200D MA$83.72

Shares out0.06B

Float0.04B

Short ratio—

Avg volume2.8M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ACLX vs LLY →ACLX vs JNJ →ACLX vs ABBV →Stock screener →